MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis

Xie, Jianfeng1; Jin, Chunchun2; Liu, Mengmeng3; Sun, Kun1; Jin, Zhanqiang1; Ding, Zhimin3; Gong, Xuehao2

2022-05-23

10.3389/fonc.2022.880336

Frontiers in Oncology   影响因子和分区

2234-943X

Purpose: For men suspected of having prostate cancer (PCa), the transrectal ultrasound (TRUS)-guided systematic biopsy (SB) was performed. MRI/TRUS fusion guided-targeted biopsy (MRI-TB) could enhance PCa detection, allowing sampling of sites at higher risk which were not obvious with TRUS alone. The aim of this systematic review and meta-analysis was to compare the detection rates of prostate cancer by MRI-TB or MRI-TB plus SB versus SB, mainly for diagnosis of high-risk PCa. Methods: A literature Search was performed on PubMed, Cochrane Library, and Embase databases. We searched from inception of the databases up to January 2021. Results: A total of 5831 patients from 26 studies were included in the present meta-analysis. Compared to traditional TRUS-guided biopsy, MRI-TB had a significantly higher detection rate of clinically significant PCa (RR=1.27; 95%CI 1.15-1.40; p < 0.001) and high-risk PCa (RR=1.41; 95% CI 1.22-1.64; p < 0.001), while the detection rate of clinically insignificant PCa was lower (RR=0.65; 95%CI 0.55-0.77; p < 0.001). MRI-TB and SB did not significantly differ in the detection of overall prostate cancer (RR=1.04; 95%CI 0.95-1.12; p=0.41). Compared with SB alone, we found that MRI-TB plus SB diagnosed more cases of overall, clinically significant and high-risk PCa (p < 0.001). Conclusion: Compared with systematic protocols, MRI-TB detects more clinically significant and high-risk PCa cases, and fewer clinically insignificant PCa cases. MRI-TB combined with SB enhances PCa detection in contrast with either alone but did not reduce the diagnosis rate of clinically insignificant PCa.

magnetic resonance imaging transrectal ultrasound prostate cancer targeted biopsy meta-analysis

SCI

英语

第一 ; 通讯

Shenzhen Science and Technology Innovation Committee[JCYJ20170413161913429] ; Shenzhen Key Medical Discipline Construction Fund[SZXK052] ; Sanming Project of Medicine in Shenzhen[SZSM201612027]

Oncology

Oncology

WOS:000807332600001

FRONTIERS MEDIA SA

Web of Science

1.Southern Univ Sci & Technol Hosp, Dept Ultrasound, Shenzhen, Peoples R China
2.Shenzhen Univ, Shenzhen Peoples Hosp 2, Dept Ultrasound, Affiliated Hosp 1, Shenzhen, Peoples R China
3.Jinan Univ, Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Shenzhen Med Ultrasound Engn Ctr,Dept Ultrasound,, Shenzhen, Peoples R China

Xie, Jianfeng,Jin, Chunchun,Liu, Mengmeng,et al. MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis[J]. Frontiers in Oncology,2022,12.

Xie, Jianfeng.,Jin, Chunchun.,Liu, Mengmeng.,Sun, Kun.,Jin, Zhanqiang.,...&Gong, Xuehao.(2022).MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis.Frontiers in Oncology,12.

Xie, Jianfeng,et al."MRI/Transrectal Ultrasound Fusion-Guided Targeted Biopsy and Transrectal Ultrasound-Guided Systematic Biopsy for Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis".Frontiers in Oncology 12(2022).